Meta-analyses of randomized trials studying the effects of treatments on vascular disease risk

Lead Research Organisation: University of Oxford

Abstract

For many drugs that influence the risk of major vascular events (heart attacks, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. For several classes of drugs (statins for heart disease and stroke, antiplatelet agents such as aspirin for diabetes, the clot-busting drug alteplase in acute stroke, and angiotensin-receptor blockers in Marfan’s Syndrome) we have established collaborations in which investigators have provided detailed individual patient data from their randomized trials that are addressing a particular clinical question. In each case we aim to generate new combined analyses that provide insights that are not apparent from the individual trials, but which only emerge when the data are combined. These analyses help to identify which patients derive the most benefit (or who are susceptible to harm), and help in developing a better understanding of how each individual treatment works. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.

Technical Summary

For many drugs that influence the risk of major vascular events (myocardial infarction, stroke, vascular disease mortality), individual trials provide only limited information about the magnitude of their effects, and their safety, in different types of patients, and the time period over which such effects emerge. This programme is focused on several ongoing collaborations in which investigators have provided detailed individual patient data from their randomized trials studying the effects of a particular class of drug. The aim in each project is to provide publications with the most comprehensive information available worldwide about the clinical benefits and risks of drugs in relevant disease areas, thereby helping to influence treatment guidelines and clinical practice.
Current work is focused on 4 main areas:
(i) The Cholesterol Treatment Trialists’ (CTT) Collaboration aims to test claims of particular side-effects of statins arising from observational studies (for example, an increased risk of cataract, sleep disturbances, memory loss, or depression), concerns about which are inhibiting prescribing of statins in patients at high risk of cardiovascular disease, with potentially adverse effects on public health. We are currently working with the sponsors of 29 large trials that have previously provided data on vascular events, cancer and mortality in order to obtain supplementary datasets on adverse events, which will then be merged with existing data. We plan to conduct meta-analyses of the effects of statins on a wide range of adverse events once data collection is complete.
(ii) In accordance with a published protocol, the Stroke Thrombolysis Trialists’ (STT) Collaboration has already reported analyses of the effects of alteplase on the proportions surviving without disability and the risks of haemorrhagic stroke in 10 trials conducted in acute ischaemic stroke. We now plan supplementary analyses of the existing database, new data collection to permit analyses of CT scan data, and the incorporation of additional data from completed or ongoing randomized trials.
(iii) The Antithrombotic Trialists’ (ATT) Collaboration is planning updated individual patient data analyses of the effects of aspirin on vascular outcomes in low-risk populations with and without diabetes, which will incorporate the results of major ongoing trials, including the Unit’s own ASCEND trial among 15,000 people with diabetes but no known history of vascular disease.
(iv) The Marfan Trialists’ Collaboration (MTC) is preparing to collect individual patient data from 10 randomized trials examining the effects of angiotensin-receptor blockers and of beta-blockers in order to reduce the rate of expansion of the aortic root, which ultimately can lead to fatal aortic rupture.

Organisations

Publications

10 25 50

publication icon
ASCEND Study Collaborative Group (2018) Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus. in The New England journal of medicine

publication icon
Baigent C (2018) Should We Increase GFR with Bardoxolone in Alport Syndrome? in Journal of the American Society of Nephrology : JASN

publication icon
Cholesterol Treatment Trialists' (CTT) Collaboration (2016) Protocol for analyses of adverse event data from randomized controlled trials of statin therapy. in American heart journal

publication icon
Gross O (2017) Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

publication icon
Herrington W (2016) Are statins useful in patients with advanced chronic kidney disease? - Authors' reply in The Lancet Diabetes & Endocrinology

 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Brigham and Women's Hospital
Department Division of Cardiovascular Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716).
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Catholic University of the Sacred Heart
Department School of Medicine (UCSC)
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716).
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Florida Atlantic University
Department Charles E. Schmidt College of Science
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716).
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation Italian Auxological Institute
Country Italy 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716).
Start Year 2006
 
Description Antithrombotic Treatment Trialists' (ATT) Collaboration 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Department Clinical Gerontology
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating aspirin for the primary prevention of vascular disease. Data are now available on 95,000 patients in 6 trials.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Our 2009 Lancet publication (373: 1849-60) has been very highly cited (over 650 citations to date) , is widely incorporated into treatment guidelines worldwide, and resulted in the MHRA issuing a warning against aspirin use for primary prevention (http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087716).
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation ANMCO Research Centre
Country Italy 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Auckland City Hospital
Country New Zealand 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Bayer
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Brigham and Women's Hospital
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Churchill Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Erasmus University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Fred Hutchinson Cancer Research Center (FHCRC)
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Glasgow Royal Infirmary
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Hamilton Health Sciences
Country Canada 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Harvard University
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Hennepin County Medical Center
Department Division of Clinical Epidemiology
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Imperial College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Jacksonville Centre for Clinical Research
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation John Radcliffe Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Leiden University Medical Center
Country Netherlands 
Sector Multiple 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Department Consorzio Mario Negri Sud (CMNS)
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Department Consorzio Mario Negri Sud (CMNS)
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mario Negri Institute for Pharmacological Research
Country Italy 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Mitsukoshi Health & Welfare Foundation
Country Japan 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Monash University
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation National Heart, Lung, and Blood Institute (NHLBI)
Country United States 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Nordic School of Public Health
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Oslo University Hospital
Department Department of Cardiology
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Oslo University Hospital
Country Norway 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Pfizer Global R & D
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Pharma Clinical
Country Israel 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Regeneron Pharmaceuticals, Inc.
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Rikshospitalet , Sogsnsavvsveien
Country Norway 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Rosalin Franklin University
Department School of Medicine Rosalin Franklin
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Royal London Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Russells Hall Hospital
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sahlgrenska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sahlgrenska University Hospital
Country Sweden 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sanofi
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sheba Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Sheba Medical Centre
Country Israel 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation St Mary's Hospital, London
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation State University of New York
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Tokai University
Country Japan 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Ulleval University Hospital
Country Norway 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation United States Department of Veterans Affairs
Country United States 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College London
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University College London Hospitals NHS Foundation Trust
Country United Kingdom 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University Hospital, Josef-Schneider-Str 2, Germany
Department Division of Nephrology
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University Hospitals of Cleveland
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Dundee
Department School of Medicine
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Glasgow
Department School of Medicine Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Gothenburg
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Iowa
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of North Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Sydney
Department NHMRC Clinical Trials Centre
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Sydney
Department Sydney Medical School
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas
Department School of Public Health Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas Health Science Center San Antonio, BrainMap Database
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Texas Southwestern Medical Center
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Washington
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation University of Wurzburg
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Uppsala University
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation VU University Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Cholesterol Treatment Trialists' (CTT) Collaboration 
Organisation Wake Forest University
Department Wake Forest School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials of LDL-lowering therapy. Data are now available on 190,000 patients in 29 trials and the CTT has published 4 major papers (over 950 citations to date) in the past 5 years.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own LDL-lowering trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact The results of the collaboration have had a major influence on lipid-lowering treatment guidelines worldwide
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation American University of Beirut
Department Epidemiology and Population Health Department
Country Lebanon 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Beijing Huilongguan Hospital
Country China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Cleveland Clinic
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Ecological Institute of Caspian Sea
Country Iran, Islamic Republic of 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Firat University
Country Turkey 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Gastrointestinal & Other Cancers Research Group
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Georgetown University
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation GlaxoSmithKline (GSK)
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Harvard University
Department Harvard Medical School
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Hospital of Psychiatry and Psychotherapy, Germany
Country Germany 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Icahn School of Medicine at Mount Sinai
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Johns Hopkins Medicine
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Johns Hopkins University
Department Johns Hopkins Bloomberg School of Public Health
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation King Fahd Hospital, Saudi Arabia
Country Saudi Arabia 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Linkoping University
Department University Medical School Linkoping
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Lund University
Country Sweden 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation MAM College of Pharmacology
Country India 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Massachusetts General Hospital
Department Cancer Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Mexican Social Security Insitute (IMSS)
Country Mexico 
Sector Public 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation New York University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Northwestern University
Department Feinberg School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Novartis
Country Global 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Ogun State University Teaching Hospital (OSUTH)
Country Nigeria 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Queen's Medical Centre
Country United Kingdom 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Rush University Medical Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Sapienza University of Rome
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Sasaki Institute
Country Japan 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Schulthess Clinic
Country Switzerland 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Seoul National University
Country Korea, Republic of 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Statistics Collaborative
Country United States 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Taipei Veterans General Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Thrombosis Center of Buenos Aires
Country Argentina 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tisch Hospital
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Toronto General Hospital
Country Canada 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tri-Services General Hospital
Country Taiwan, Province of China 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Trinity College Dublin
Country Ireland 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tripler Medical Army Center, US
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Tufts University
Department School of Dental Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Arizona
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Cagliari
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Chieti-Pescara
Country Italy 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Louisville
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Lyon
Country France 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Maryland
Department School of Medicine Maryland
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Ottawa
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Pennsylvania
Department Institute for Translational Medicine and Therapeutics (ITMAT)
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Southern California
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Toronto
Country Canada 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Utah
Department School of Medicine Utah
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Zagreb
Country Croatia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation University of Zaragoza
Country Spain 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Coxib and traditional NSAID Treatment (CNT) Collaboration 
Organisation Vanderbilt University
Department Vanderbilt Medical Center
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from all large-scale trials evaluating coxibs and traditional NSAIDs.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact European Medicines Agency recommends the same cardiovascular precautions for diclofenac as for selective COX-2 inhibitors as a result of reviewing the new evidence from our meta-analysis.
Start Year 2006
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Boehringer Ingelheim
Country Germany 
Sector Private 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Cedars-Sinai Medical Center
Country United States 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Florey Neurosciences Institute Melbourne Australia
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation George Institute for Global Health
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Helsinki University Central Hospital
Country Finland 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Mayo Clinic
Country United States 
Sector Charity/Non Profit 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation National Cerebral and Cardiovascular Centre
Country Japan 
Sector Hospitals 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Stanford University
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation Technical University of Dresden
Country Germany 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Alabama at Birmingham
Department School of Medicine
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Edinburgh
Department School of Molecular and Clinical Medicine Edinburgh
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Glasgow
Department School of Medicine Glasgow
Country United Kingdom 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Melbourne
Country Australia 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description Stroke Thrombolysis Trialists' (STT) Collaboration 
Organisation University of Texas
Country United States 
Sector Academic/University 
PI Contribution CTSU coordinates the collection and analysis of individual participant data from of all eligible and available trials of thrombolysis with rt-PA after acute ischaemic stroke.
Collaborator Contribution Collaborators provide individual participant data and other supporting information from their own trials and through the regular meetings of the collaboration provide input to the questions to be addressed, preparation of analysis plans and discussion of results.
Impact Recent Lancet paper (2014: http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2814%2960584-5/fulltext) results of meta-analysis clearly showed that alteplase given promptly after stroke reduces long-term disability.
Start Year 2011
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Academic Medical Center
Country Netherlands 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Antwerp University Hospital
Department Center for Medical Genetics
Country Belgium 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation BC Children's Hospital
Department Children's Heart Centre
Country Canada 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Bichat-Claude Bernard Hospital
Department French National Reference Centre for Marfan Syndrome
Country France 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Boston Children's Hospital
Country United States 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Fondazione IRCCS Policlinico San Matteo
Country Italy 
Sector Charity/Non Profit 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Massachusetts General Hospital
Country United States 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation National Heart, Lung, and Blood Institute (NHLBI)
Country United States 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation National Taiwan University
Department Department of Pediatrics
Country Taiwan, Province of China 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation New England Research Institutes Watertown
Country United States 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Royal Brompton Hospital
Department Clinical Trials and Evaluation Unit
Country United Kingdom 
Sector Public 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University College London
Department Institute of Cardiovascular Science
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University of East Anglia
Department Faculty of Medicine and Health Sciences
Country United Kingdom 
Sector Academic/University 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation University of Ghent
Department Centre for Medical Genetics
Country Belgium 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description The Marfan Treatment Trialists' Collaboration 
Organisation Vall d'Hebron University Hospital
Department Department of Cardiology
Country Spain 
Sector Hospitals 
PI Contribution The collaboration was created in 2012 with the Department of Cardiovascular Medicine, Oxford and will bring together the individual patient data from all randomised trials of angiotensin receptor antagonists/blockers (ARBs) in Marfan syndrome.
Collaborator Contribution Individual collaborators will provide individual patient data for meta-analysis according to a recently finalised protocol and statistical analysis plan.
Impact None.
Start Year 2012
 
Description NDPH participant panel 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact Presentation of Cholesterol Treatment Trialists' Collaboration (CTT) and Marfan Treatment Trialists' Collaboration (MTT) to the Nuffield Department of Population Health Participant Panel
Year(s) Of Engagement Activity 2017
URL https://www.ctsu.ox.ac.uk/research/participant-panel